New approaches for patients with advanced radioiodine-refractory thyroid cancer

Table 2 Summary of the efficacy and safety of sorafenib in patients with thyroid cancer reported by clinical trials

Ref.	n	Type	PR, %	SD, %	Median	Median	Most frequent AE	Most frequent grade 3-4 AE
					PFS (mo)	OS (mo)
Gupta-Abramson et al[77], 2008	27	DTC	26	59	19	-	HFS, 93%	Hypertension, 13%
Kloos et al[78], 2009	33	PTC	15	57	16	23	Fatigue, 85%	Fatigue, 16%
Hoftijzer et al[79], 2009	31	DTC	25	34	14.5	-	HFS, 66%	HFS, 18%
Cabanilas et al[59], 2010	13	DTC	20	60	19		HFS, 60%	-
Keefe et al[80], 2011	47	DTC/PD	38	47	22	32.4	-	-
Ahmed et al[81], 2011	19	DTC	16	-	-	-	Dermatology (other than HFS), 88%	HFS, 44%
Chen et al[82], 2011	9	DTC	33	44	10.5	-	Alopecia, 100%	-
Marotta et al[83], 2012	17	DTC	30	41	9	10	HFS, 88%
Schneider et al[84], 2012	31	DTC	31	42	18	34.5	HFS, 71%	HFS, 22%
Capdevilla et al[85], 2012	16	DTC	19	50	13.3	23.6	HFS and diarrhea, 62%	HFS, 23%
Brose et al[6], 2014	207	DTC	12	42	10.8	.	HFS, 73.6%	HFS, 20.3%
Benekli et al[86], 2014	14	DTC	-	43	21.3	-	-	HFS, 22%
Dadu et al[87], 2008	51	DTC	-	-	-	56	-	-
Luo et al[88], 2014	8	DTC	50	37	9.4	12.8	Alopecia, 75%	Hypocalcemia and serum amylase increased, 12.5%
Gallo et al[89], 2015	20	DTC	25	40	8.2	28.4	Fatigue, 95%	Gastrointestinal symptoms, 15%
Kim et al[90], 2018	98	DTC	25	37	9.7	-	HFS, 76%	HFS, 41%
Jerkovich et al[12], 2019	18	DTC	11	72	16.5	-	HFS, 67%	HFS, 14%

DTC: Differentiated thyroid carcinoma. PR: Partial response; PFS: Progression free survival; SD: Stable disease; OS: Overall survival; AE: Adverse event.